Abstract:To investigate the effects of anti-GPC3 antibody on the Wnt/catenin pathway in liver cancer biology, thus providing a new target for the biological treatment of the disease. A total of 12 BALB/C experimental nude mice were selected as experimental objects. The mice were all male, weighed 15–20 g and aged 4–5 weeks. First, mouse liver cancer models were constructed. Then, the HepG2 liver cancer cells in logarithmic growth period were inoculated into the caudal veins of mouse models. On the 3rd day after inoculation, the tumor formations of nude mice were observed. Second, the anti-GPC3 antibody was designed and constructed, and the activity of anti-GPC3 antibody was detected. The mouse models were divided into the experimental group (EG) and the control group (CG), with 6 mice in each group. In the EG, mice were injected with 3 mg/kg of anti-GPC3 antibody in the caudal veins once a day for three consecutive days, while in the CG mice were injected with the same amount of saline as the control. Mice in both groups received 3 injections in total. After the last administration, all mice were euthanized using the decapitation method following anesthesia with ethyl ether. The liver cancer cells of nude mice were extracted and cultured in DMEM medium. The effects of anti-GPC3 antibody on Wnt/ β -catenin in liver cancer nude mice and the effects of anti-GPC3 antibody on epithelial-mesenchymal transition (EMT) in mouse liver cancer cells were observed. The bodyweight, liver weight and index of mice in the EG increased significantly ( P < 0.05). The serum alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP) levels of mice in the EG were reduced than those in the CG ( P < 0.05). Compared with the CG, the superoxide dismutase (SOD) concentration increased, while the malonaldehyde (MDA) concentration decreased in the liver tissues of mice in the EG ( P < 0.05). There was binding activity between GPC3 recombinant protein and the antibody; the affinity constant was K D = 1.4 × 10 –6 M, compared with the commercial anti-GPC3 antibody, the affinity constant was lower. The interference effects of siRNA on anti-GPC3 antibody were detected by Western Blot. After the injection of anti-GPC3 antibody, the expression of β -catenin siRNA in liver cancer cells decreased significantly. The optical microscope images of mouse liver cancer cells in groups were compared. Through down-regulating the Wnt/ β -catenin by anti-GPC3 antibody, the morphology of epithelial cells was maintained, the cells were arranged orderly, the cubic structure was kept stable, and the occurrence of EMT was reduced. However, in the CG, the structure of mouse liver cancer cells was disordered, the obvious EMT occurred ( P < 0.05). Through down-regulating the expression of Wnt/ β -catenin by anti-GPC3 antibody, the invasiveness, and metastasis of liver cancer cells could be effectively inhibited. Compared with the CG, the number of cells passing through the chamber was significantly reduced ( P < 0.05). The anti-GPC3 antibody had inhibitory effect on Wnt/ β -catenin signaling pathway. The occurrence of EMT and the invasiveness of liver cancer cells were inhibited effectively. Therefore, the anti-GPC3 antibody could be used as a reference for clinical molecular targeted therapy of liver cancer.

Suppression of Liver Regeneration and Hepatocyte Proliferation in Hepatocyte-Targeted Glypican 3 Transgenic Mice

Investigation of the Role of Glypican 3 in Liver Regeneration and Hepatocyte Proliferation.

Regulation of Liver Growth by Glypican 3, CD81, Hedgehog, and Hhex.

Glypican-3 deficiency in liver cancer upregulates MAPK/ERK pathway but decreases cell proliferation

Regulation Of Glucose Homeostasis And Lipid Metabolism By Ppp1r3g-Mediated Hepatic Glycogenesis

Elevated GPC3 level promotes cell proliferation in liver cancer.

Inhibition of Glypican-3 Expression Via RNA Interference Influences the Growth and Invasive Ability of the MHCC97-H Human Hepatocellular Carcinoma Cell Line

Glypican‐3: A Promising Biomarker for Hepatocellular Carcinoma Diagnosis and Treatment

Deletion of Golgi Protein 73 Delayed Hepatocyte Proliferation of Mouse in the Early Stages of Liver Regeneration.

Glypican-3 knockdown inhibits the cell growth, stemness, and glycolysis development of hepatocellular carcinoma cells under hypoxic microenvironment through lactylation

Glypican-3 Enhances Reprogramming of Glucose Metabolism in Liver Cancer Cells

Glypican-3 Inhibits Hedgehog Signaling During Development by Competing with Patched for Hedgehog Binding

Expression of Glypican 3 Enriches Hepatocellular Carcinoma Development-Related Genes and Associates with Carcinogenesis in Cirrhotic Livers

Long noncoding RNA GPC3-AS1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.

Glypican-3: a new target for cancer immunotherapy

Knockdown of Golgi Phosphoprotein 2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Motility

GPC-3 in Hepatocellular Carcinoma: Current Perspectives

Glypican-3 Promotes Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells Through Erk Signaling Pathway

Loss of Gsα impairs liver regeneration through a defect in the crosstalk between cAMP and growth factor signaling

The Inhibitory Effects of Anti-GPC3 Antibody on Wnt/β-Catenin Signaling Pathway as a Biological Therapy in Liver Cancer

Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior